Biomarkers and receptor targeted therapies reduce clinical trial risk in Non-Small-Cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 2, 2014, Pages 163-169

  Falconi, Adam ^a   Lopes, Gilberto ^b,c,d   Parker, Jayson L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HCor Onco   (Brazil)

^c Oncoclinicas Do Brasil   (Brazil)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Drug development; Non small cell lung cancer; Risk analysis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; HLA ANTIGEN; INTERLEUKIN 4 RECEPTOR; LEWIS Y ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PEMETREXED; PLATINUM; PROTEIN NRAS; RECEPTOR; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BRAF ONCOGENE; CANCER PATIENT; CANCER STAGING; COST CONTROL; COST OF ILLNESS; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893426784     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000075     Document Type: Article

References (23)

1. World Health Organisation. Section of Cancer Information. GLOBOCAN-2008. Lyon, France: IARC; 2008.
2. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-216.
3. Giaccone G, Smit E. Lung cancer. Updat Can Therap 2006;1 (2):235-272.
4. Parker JL, Clare Kohler J. The success rate of new drug development in clinical trials: Crohns disease. J Pharm Pharm Sci 2010;13:191-197.
5. Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat 2012;136:179-185.
6. Parker JL, Zhang ZY, Buckstein R. Clinical trial risk in Non-Hodgkins lymphoma: endpoint and target selection. J Pharm Pharm Sci 2011;14:227-235.
7. Osborne BJW, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: the effect of drug class. J Pharm Health Serv Res 2011;2:211-216
8. Tenuta A, Klotz L, Parker JL. Clinical trial risk in castration resistant prostate cancer: immunotherapies show promise. BJU I June 17, 2013 [Epub ahead of print].
9. Jayasundara KS, Keystone EC, Parker JL. Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis. J Rheumatol 2012;39:2066-2070.
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Bevacizumab NDA 202570 approval letter, October 11, 2006. Available at: http://www.accessdata.fda.gov/drugsatfdadocs/appletter/2006/125085s085ltr. pdf. Accessed on November 7, 2012.
11. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Gefitinib NDA 21-399 approval letter, May 5, 2003. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2003/21-399-IRESSA-Approv.pdf. Accessed on November 7, 2012.
12. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Erlotinib NDA 21-743 approval letter, November 18, 2004. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2004/21743ltr.pdf. Accessed on November 7, 2012.
13. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Pemetrexed NDA 21-677 approval letter, August 19, 2004. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2 004/21677, 21462s001ltr.pdf. Accessed on November 7, 2012.
14. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Crizotinib NDA 202570 approval letter, August 26, 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/202570s000ltr.pdf. Accessed on November 7, 2012.
15. DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: Success rates of investigational drugs. Clinic Pharmacol Therap 2010;87(3):272-277.
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines Non-small cell lung cancer Version 3.2011.
17. USP Medicare Model Guidelines. Available at: http://www.usp.org/usp- healthcare-professionals/medicare-model-guidelines Accessed on December 7, 2013.
18. National Cancer Institute (NCI): Targeted Cancer Therapies. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted Accessed on December 7, 2013.
19. Harrington, SE. Cost of capital for pharmaceutical, biotechnology, and medical devices firms. In The Handbook of the Economics of the Biopharmaceutical Industry, Draft ed. Oxford, England: Oxford University Press; 2009.
20. Pfizer, Inc. Xalkori (Crizotinib) Prescribing information. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed on January 15, 2013.
21. Marrer E, Dieterle F. Biomarkers in oncology drug development: rescuers or troublemakers? Expert Opin Drug Metab Toxicol 2008;4:1391-402.
22. Simon R. Translational research in oncology: key bottlenecks and new paradigms. Expert Rev Mol Med 2010;12:e32.
23. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-185.